FindTrial
Sign In

PD-L1 t-haNK

BIOLOGICAL6 trials

Sponsors

ImmunityBio, Inc., National Cancer Institute (NCI), Dana-Farber Cancer Institute

Conditions

Advanced HNSCCAdvanced Triple Negative Breast CancerGastroesophageal Junction (GEJ) CancersGlioblastomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaLocally Advanced Solid TumorMetastatic Cancer

Phase 1

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
CompletedNCT04050709
ImmunityBio, Inc.Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
Start: 2019-07-18End: 2026-03-25Updated: 2026-04-01
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
TerminatedNCT04927884
ImmunityBio, Inc.Advanced Triple Negative Breast Cancer
Start: 2021-09-08End: 2022-12-12Updated: 2024-06-12

Phase 2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Active, not recruitingNCT04390399
ImmunityBio, Inc.Pancreatic Cancer
Start: 2020-07-21End: 2026-05-31Target: 328Updated: 2025-12-15
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
CompletedNCT04847466
National Cancer Institute (NCI)Advanced HNSCC, Gastroesophageal Junction (GEJ) Cancers
Start: 2021-12-14End: 2026-01-06Updated: 2026-06-01
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Active, not recruitingNCT06061809
ImmunityBio, Inc.Glioblastoma
Start: 2024-08-07End: 2030-12-31Target: 34Updated: 2026-07-01
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RecruitingNCT06239220
Dana-Farber Cancer InstituteHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer +3
Start: 2024-02-16End: 2027-03-31Target: 25Updated: 2026-08-18

Related Papers

Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).
Journal of Clinical Oncology2026-05-28
Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3 <sup>rd</sup> line or greater metastatic pancreatic cancer.
Journal of Clinical Oncology2025-05-28
Abstract 5255: Systemic immunosuppression in pancreatic cancer
Cancer Research2025-04-21
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
2025-02-1410 citations
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
Future Oncology2023-05-185 citations
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
Journal of Clinical Oncology2022-06-015 citations
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Journal of Clinical Oncology2022-01-195 citations
Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
Journal of Clinical Oncology2021-05-203 citations
Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.
Journal of Clinical Oncology2020-05-207 citations